Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Call Transcript February 13, 2025Ultragenyx Pharmaceutical Inc. misses on earnings expectations.
Ultragenyx Pharmaceutical Inc. (RARE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,739,813 | $73,193,933 | -13% | 2.78% |
| 2. | Alkeon Capital Management Panayotis Takis Sparaggis | 1,686,716 | $70,960,143 | -44% | 0.14% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,576,114 | $66,307,116 | 0.7% | |
| 4. | Vestal Point Capital Ryan Wilder | 1,500,000 | $63,105,000 | +100% | 3.74% |
| 5. | Alyeska Investment Group Anand Parekh | 1,439,740 | $60,569,862 | +24% | 0.22% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.63 | 5,000 | Officer, Director | 472,479 | 2019-09-11 | Filing | |
| $52.96 | 1,647 | Officer, Director | 2,559,741 | 2017-08-28 | Filing | |
| $52.40 | 5,853 | Officer, Director | 2,558,094 | 2017-08-28 | Filing | |
| $21.00 | 175,000 | Large Shareholder, Other | 3,260,240 | 2014-01-31 | Filing | |
| $21.00 | 4,500 | Officer | 84,255 | 2014-01-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $42.10 | 6,028 | 265,238 | 2025-03-03 | Filing | ||
| $42.10 | 12,846 | 75,287 | 2025-03-03 | Filing | ||
| $42.10 | 8,945 | 71,922 | 2025-03-03 | Filing | ||
| $42.10 | 14,439 | 107,766 | 2025-03-03 | Filing | ||
| $42.48 | 25,000 | 2,158,985 | 2025-02-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,034,862 | $422,166,645 | 0% | |
| 2. | 6,536,517 | $274,991,271 | 0% | |
| 3. | 4,298,003 | $180,816,986 | 0.53% | |
| 4. | 2,722,624 | $114,540,792 | 0% | |
| 5. | 2,457,543 | $103,388,833 | 0.01% |
News See All
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to the Ultragenyx Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Ultragenyx Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-2.02505 EPS, expectations were $-1.72.
5 NASDAQ Stocks with Biggest Upside
Based on 12 Wall Street analysts’ ratings in the last three months, Rivian Automotive, Inc. (NASDAQ:RIVN) has a consensus rating of Moderate Buy.
10 Biotech Stocks with Huge Potential
In this article, we will take a look at the 10 biotech stocks with huge potential.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. beats earnings expectations. Reported EPS is $-1.52, expectations were $-1.65. Ultragenyx Pharmaceutical Inc.
Billionaire Hedge Funds
